Tysabri - Natalizumab - Dosage - Side Effects - Drug Interactions
Tysabri (natalizumab) drug information, dosage, side effects, drug interactions, and warnings. Tysabri, generic name natalizumab, is a selective adhesion molecule inhibitor. Tysabri was FDA approved 11/2004 for MS, but later withdrawn in 02/2005. Tysabri was also being studied for arthritis treatment. In 06/2006, it was reintroduced to treat relapsing forms of MS.
Tysabri (Natalizumab) Information Center
On June 5, 2006, Biogen Idec and Elan announced that the FDA approved a supplemental Biologics License Application (sBLA) for the reintroduction of Tysabri (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses, from Biogen Idec.
On June 5, 2006, Biogen Idec and Elan announced that the FDA approved a supplemental Biologics License Application (sBLA) for the reintroduction of Tysabri (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses, from Biogen Idec.
Drug Monograph: Tysabri / Natalizumab
Natalizumab is the first FDA-approved alpha-4-integrin inhibitor. Natalizumab is administered parenterally as an intravenous infusion.
Natalizumab is the first FDA-approved alpha-4-integrin inhibitor. Natalizumab is administered parenterally as an intravenous infusion.
Patient Education: Tysabri / Natalizumab Injection
Patient education for Tysabri / natalizumab injection.
Patient education for Tysabri / natalizumab injection.
05/07/2007 Tysabri History: Tysabri Still Holding Strong
05/07/2007, After less than four months on the market, Tysabri was withdrawn after the FDA issued a public health advisory. Its manufacturer, Biogen, withdrew Tysabri in February 2005 after two patients in clinical trials died from PML. In June 2006, the FDA approved Tysabri under the condition that any patients taking the drug register with a program designed to ensure its safe use.
05/07/2007, After less than four months on the market, Tysabri was withdrawn after the FDA issued a public health advisory. Its manufacturer, Biogen, withdrew Tysabri in February 2005 after two patients in clinical trials died from PML. In June 2006, the FDA approved Tysabri under the condition that any patients taking the drug register with a program designed to ensure its safe use.
Multiple Sclerosis Treatments
There are many considerations when deciding which therapy to begin, including: side effects, type of MS you have, ease of use and any necessary monitoring.
There are many considerations when deciding which therapy to begin, including: side effects, type of MS you have, ease of use and any necessary monitoring.
CenterWatch Newly Approved Drug Therapies: Tysabri (Natalizumab)
Tysabri (Natalizumab) is a recombinant humanized IgG4k monoclonal antibody produced in murine myeloma cells. In development, Tysabri was originally slated to be named Antegren, but FDA regulators forced a change due to name confusion with existing products such as Integrilin and Edecrin, from CenterWatch.
Tysabri (Natalizumab) is a recombinant humanized IgG4k monoclonal antibody produced in murine myeloma cells. In development, Tysabri was originally slated to be named Antegren, but FDA regulators forced a change due to name confusion with existing products such as Integrilin and Edecrin, from CenterWatch.